News
| 2 min read
The therapy crosses the blood-brain barrier after peripheral injection and delivers behavioral improvements that last up to seven days.
| 3 min read
This recognition signals momentum for next-gen RNA therapeutics designed to enhance delivery and efficacy in treating rare genetic diseases.
| 3 min read
Largest molecular analysis to date reveals more than 100 blood biomarkers tied to the disease.
| 5 min read
A wave of FDA rejections reveals how CMC issues are becoming a leading barrier to approval in cell and gene therapy development.
| 4 min read
Big-ticket licensing, FDA shake-ups, and Alzheimer’s data led the news this week.
| 3 min read
Researchers challenge decades-old assumptions about fragile protein cores, opening new paths for faster drug and enzyme design.
| 8 min read
By starting with T cells from healthy donors, Allogene is manufacturing off-the-shelf CAR T cell therapies that patients don’t have to wait for.
| 3 min read
Insilico’s Phase 2a trial of an AI-designed therapy marks a milestone in data-driven drug development.
| 4 min read
Another death linked to Sarepta’s gene therapy, a promising glioblastoma trial, a rejection for Replimune, and more led the news this week.
| 2 min read
By focusing on chemistry rather than biology alone, Actithera is aiming to elevate radiopharmaceuticals from niche applications to standard-of-care contenders.
| 3 min read
Point-of-care tests that detect biomarkers from menstrual blood can enable broader access to disease monitoring and diagnosis.
| 4 min read
Researchers showed that insulin resistance exists on a spectrum among diabetics and healthy controls.
